Thalidomide, a selective inhibitor of tumor necrosis factor a (TNF-a) synthesis, suppresses the activation of latent human immunodeficiency virus type 1 (HIV-1) in a monocytoid (U1) line. The inhibition is dose dependent and occurs after exposure of the ceils to recombinant TNF-a, phorbol myristate acetate, lipopolysaccharide, and other cytokine combinations. Associated with HIV-1 inhibition is a reduction in agonist-induced TNF-a protein and mRNA production. Thalidomide inhibition of vims replication in the phorbol myristate acetate-and recombinant TNF-a-stimulated T-ceil line ACH-2 is not observed. The presence of thalidomide also Inhibits the activation of virus in the peripheral blood mononuclear cells of 16 out of 17 patients with advanced HIV-1 infection and AIDS. These results suggest the use of thalidomide in a clinical setting to inhibit both virus replication and the TNF-a-induced systemic toxicity of HIV-1 and opportunistic infectious.
The human immunodeficiency virus type 1 (HIV-1) infects T cells and monocytes in both a latent and productive manner (1) (2) (3) . Replication of HIV-1 in cell lines and in cells from infected patients often requires an agonist to activate the cell and its latent virus (4) . Cytokines such as granulocytemacrophage colony-stimulating factor (GM-CSF), interleukin (IL) 3, and IL-6 upregulate virus expression, whereas tumor necrosis factor a (TNF-a) is a particularly potent activator (5) (6) (7) (8) (9) .
To better understand the role of TNF-a in HIV-1 activation, we have studied the effects ofa selective inhibitor ofthis cytokine. We have recently shown that thalidomide (Napthalimidoglutarimide) selectively inhibits the production of human peripheral blood mononuclear cell (PBMC) TNF-a when these cells are induced in vitro with lipopolysaccharide (LPS) and other agonists (10) . Thalidomide has also been shown to reduce serum TNF-a levels in lepromatous leprosy patients with erythema nodosum leprosum, in association with the disappearance of the clinical symptoms (11) .
Studies were conducted on chronically HIV-1-infected, promonocytic Ul (12) and T-lymphocytic ACH-2 (8, 13 ) cell lines, as well the peripheral blood cells of HIV-1+ patients. In this manuscript, HIV-1 activation in response to a number of stimuli was evaluated and correlated with the production of TNF-a by these cells. We demonstrate that thalidomide inhibits TNF-a mRNA levels and TNF-a protein as well as the expression of HIV-1 in infected cell lines. Thalidomide was also shown to inhibit HIV-1 activation in PBMCs of infected patients. The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. (12) . The ACH-2 cell line was produced by infection ofA3.01 cells with HIV-1 (8, 13) . Cells were grown in RPMI 1640 medium (Mediatech, Cellgro, Herndon, VA) supplemented with 10%6 (vol/vol) fetal bovine serum (FBS) (GIBCO), 2 mM glutamine, penicillin at 100 units/ml, and streptomycin at 100 jAg/ml (GIBCO) (complete medium poly(rA)-(dT)j2_j8 (Pharmacia LKB) per ml in 50 mM Tris, pH 7.8/7.5 mM KCl/2 mM dithiothreitol/5 mM MgC92/0.05% Nonidet P-40/32P-labeled dTTP (Amersham) at 10 XCi/ml (1 Ci = 37 GBq). The mixture was incubated for 90 min at 37°C and spotted onto DE81 ion-exchange chromatography paper (Whatman), and the radioactivity was measured as described (14) . The percent inhibition of RT = 100 x [1 -(cpm of stimulator with inhibitor -cpm of medium with inhibitor)/ 0  851  100  780  100  5  593  70  300  38  10  458  54  0  0  50  335  39  0  0  rIL6 + LPS  0  251  100  200  100  5  268  108  170  85  10  235  92  100  50  50 156 60 10 5 r, Recombinant.
MATERIAL AND METHODS
*RT activity in triplicate culture supernatants was evaluated at 48 h.
The RT value (mean + SEM) in the absence of agonist stimulation was 52 ± 41 cpm. tTNF-a activity in triplicate culture supernatants evaluated at 20 h. tPercent of maximal RT activity. Percent of maximal TNF-a production.
(cpm of stimulator without inhibitor -cpm of medium without inhibitor)].
Viral p24 Antigen (Ag) Assay. Cell culture supernatants were assayed for p24 Ag activity by using the DuPont HIV-1 p24 core profile ELISA kit (DuPont/NEN). The absorbance of each sample was determined at 490 nm with an MR 700 microplate reader (Dynatech). Optical densities (OD) for duplicate samples were averaged. Percent inhibition of p24 Ag = 100 x [1 -(mean OD with DMSO and inhibitor/mean OD with DMSO)].
TNF-a Assay. Cell culture supernatants were assayed in triplicate for the amount of TNF-a by using an ELISA kit (Endogen, Boston) as described by the manufacturer.
HIV-1+ Patients. After informed consent was obtained, a total of 17 HIV-1-seropositive adult participants were seen either as outpatients or inpatients at The Rockefeller University Hospital or as inpatients at Bellevue Hospital or New York Hospital. The patients were predominantly male, aged 25-49, and in Centers for Disease Control class II-IV (15, 16) . Patients with lymphomas were excluded. Most patients were on the antiretroviral agents zidovudine, didanosine, or both (see Table 4 tration of 106 cells per ml in six-well plates (Falcon). Cultures were set up without DMSO or inhibitor, with 0.2% DMSO alone, and with 0.2% DMSO in combination with thalidomide at concentrations of 10 and 20 ,ug/ml. Cultures were incubated at 37°C with 5% CO2 for 7 days and sampled every 24 h, and supernatants were stored at -70°C until assayed. TNF-a ELISAs were performed on 24-h (day 1) supernatants; p24 Ag ELISAs were performed on day 3 and 4 supernatants and, if not positive, on day 5, 6, and 7 supernatants. RT assays were done on day 6 and 7 supernatants. Extensive cell death was recorded from day 8 for 15 min at room temperature with 2x SSC/0. 1% SDS, 30 mm at RT with 0.1x SSC/0.1% SDS, and 30 min at 60°C with 0.1x SSC/0.1% SDS. After air drying, the blots were exposed to x-ray film for 12-24 h at -70°C and developed in a Kodak X-Omat processor stand. Densitometry was performed using a Phosphorlmager (Molecular Dynamics, Sunnyvale, CA), and results were expressed as density units.
RESULTS Thalidomide Inhibits IHV-1 Activation in Promonocytic Ul
CeDls. Culture ofUl cells leads to little virus expression unless the cells are stimulated with an agonist such as TNF-a. More than a 5-fold increase in RT activity was noted with TNF-a at 1 ng/ml (Fig. 1) . The addition of thalidomide at 5-50 pg/ml inhibited the TNF-a-induced release ofRT by as much as 70%. The inhibitory effect of thalidomide on RT activity did not result from cytotoxicity since neither the proliferation nor the viability of Ul cells was influenced (Fig. 1 legend) .
The inhibition of virus expression was observed only when thalidomide was present during the period of agonist-induced activation with TNF-a. If the cells were preincubated with the drug and washed before stimulation, inhibition did not occur. A similar effect of thalidomide was observed with the other stimuli shown in Table 1 .
Effect ofThalidomide on HIV-1 Activation of the T-Cell Line ACH-2. Activation of latent HIV-1 in the T-cell line ACH-2 is easily achieved by culture of the cells with TNF-a as well as with PMA. However, as shown in Table 2 , thalidomide at 5-50 pg/ml failed to inhibit viral expression by >20%o. The drug did not influence ACH-2 cell number or viability ( Table  2 legend).
The Effect of Thalidomide on TNF-a mRNA and Protein Production by Ul Cells. The stimulation of Ul cells by PMA or IL-6 plus LPS induced extensive production of TNF-a. Table 3 indicates that, after PMA or IL-6 plus LPS stimulation, thalidomide inhibited viral activation as well as the production ofTNF-a by Ul cells. PMA stimulation ofthe Ul cells induced TNF-a mRNA, and the level of this message was inhibited by thalidomide at 20 and 50 p,g/ml (Fig. 2) . Although ACH-2 cells treated with PMA also demonstrated enhanced TNF-a mRNA, this mRNA production was not inhibited by thalidomide. The thalidomide suppression of RT in the cells stimulated with IL-6 plus LPS and GM-CSF plus LPS was also correlated with decreased TNF-a mRNA (Fig.  3) .
The ability of TNF-a to induce endogenous TNF-a mRNA could be demonstrated only in the presence of cycloheximide. Under these conditions, TNF-a mRNA was also inhibited by the presence of thalidomide (Fig. 4) . Therefore endogenously synthesized TNF-a may play a role in viral activation, and its inhibition by thalidomide could inhibit virus production (10, 11) .
The Effect of Thalidomide on the PBMCs of Patients with HIV-1 Infection and AIDS. The studies on cell lines were extended to the circulating cells of HIV-i-infected individuals. A dose-dependent inhibition by thalidomide of both the p24 Ag and RT activity was noted in PBMCs from six patients with low blood CD4+ T-cell counts (9-41 cells per mm3) (data not shown). Table 4 demonstrates the inhibitory effect of thalidomide on HIV-1 activation in PBMCs obtained from 17 HIV-1+ donors, evaluated by p24 Ag ELISA. In most individuals, an inhibition of HIV-1 activation was observed. In some donors with higher CD4+ T-cell counts, HIV-1 activation and p24 Ag expression took longer than 7 days, and thalidomide inhibition could not be analyzed because of reduced cell viability (Table 4 legend) .
DISCUSSION
Thalidomide, a selective inhibitor of TNF-a production by monocytes, significantly reduces HIV-1 replication in PBMCs from HIV-1-infected hosts and in agonist-stimulated latently infected cell lines. In both situations, either an agonist or amplifying mechanisms are necessary to activate cells with latent virus. Thalidomide has a pronounced inhibitory effect on TNF-a and TNF-a mRNA production by the Ul monocytic line activated with recombinant TNF-a or with a group of other agonists, which include PMA, other cytokines, and endotoxin. This suggests that HIV-1 activation §Inhibition demonstrated at a thalidomide concentration of 10 pg/ml. under these in vitro conditions could proceed by way of a common TNF-a-dependent pathway. Studies on the mechanism of thalidomide action in monocytes (20) indicate that the drug functions by selectively accelerating the decay ofthe TNF-a mRNA. The situation is less clear when one considers the T-cell line ACH-2. Here viral activation is readily accomplished with recombinant TNF-a as well as PMA, yet thalidomide inhibition never exceeds 20%. TNF-a mRNA production by these cells is, however, easily demonstrated. These differences in T-cell and monocytoid cell lines may reflect separate pathways necessary for viral activation, as reported (20, 21) . In addition, the mechanism whereby TNF-a influences these pathways may also be distinct. It is of interest that pentoxifylline, another TNF-a inhibitor that blocks TNF-a mRNA transcription, also fails to inhibit HIV-1 replication in lymphoid cells but does so in monocytoid cells (ref. 22 ; G.K., unpublished results). This suggests that the thalidomide inhibition of viral activation in infected PBMCs is expressed through the monocyte population.
The role of TNF-a in infections and inflammatory processes depends, in part, upon its concentration in the blood and tissues. Low levels are sufficient and necessary to promote host resistance (23, 24) . However, higher levels of TNF-a lead to systemic toxicity and even death. Considering the application ofthese results to the therapy ofhuman HIV-1 infections, two positive results might be anticipated. First, thalidomide and/or its congeners may suppress viral replication and decrease viral burden. Second, it may enhance patient well-being by reducing TNF-a-induced fever, malaise, muscle weakness, and the cachexia of the immunodepressed host.
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